AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

被引：42
|
作者：
Fong, P. C.
Boss, D. S.
Carden, C. P.
Roelvink, M.
De Greve, J.
Gourley, C. M.
Carmichael, J.
De Bono, J. S.
Schellens, J. H.
Kaye, S. B.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] UZ Brussel, Ctr Oncol, Brussels, Belgium
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[5] Kudos Pharmaceut, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I trial of AZD2281 (KU-0059436), a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient tumours
    de Bono, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 20 - 20
  • [2] Discovery of olaparib (AZD2281; KU-0059436): A novel, bioavailable inhibitor of poly(ADP-ribose)polymerase
    Rudge, David A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [3] Human biotransformation of olaparib (AZD2281) an oral poly(ADP-ribose) polymerase (PARP) inhibitor
    Clarkson-Jones, J.
    Page, C.
    Sarda, S.
    Swaisland, H.
    EJC SUPPLEMENTS, 2010, 8 (07): : 132 - 132
  • [4] Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
    Jens Samol
    Malcolm Ranson
    Edwina Scott
    Euan Macpherson
    James Carmichael
    Anne Thomas
    James Cassidy
    Investigational New Drugs, 2012, 30 : 1493 - 1500
  • [5] Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
    Samol, Jens
    Ranson, Malcolm
    Scott, Edwina
    Macpherson, Euan
    Carmichael, James
    Thomas, Anne
    Cassidy, James
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1493 - 1500
  • [6] First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (KU), a small molecule inhibitor of poly ADP-RIBOSE polymerase (PARP) in cancer patients (P), including BRCA 1/2 mutation carriers
    de Bono, J.
    Boss, D.
    Fong, P.
    Roelvink, M.
    Yap, T.
    Tutt, A.
    Mortimer, P.
    O'Connor, M.
    Schellens, J. H.
    Kaye, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 27
  • [7] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours.
    Fong, P. C.
    Spicer, J.
    Reade, S.
    Reid, A.
    Vidal, L.
    Schellens, J. H.
    Tutt, A.
    Harris, P. A.
    Kaye, S.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 126S - 126S
  • [8] First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers
    Yap, T. A.
    Boss, D. S.
    Fong, P. C.
    Roelvink, M.
    Tutt, A.
    Carmichael, J.
    O'Connor, M. J.
    Kaye, S. B.
    Schellens, J. H.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
    Audeh, M. W.
    Penson, R. T.
    Friedlander, M.
    Powell, B.
    Bell-McGuinn, K. M.
    Scott, C.
    Weitzel, J. N.
    Carmichael, J.
    Tutt, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells
    Zhan, L.
    Qin, Q.
    Lu, J.
    Liu, J.
    Zhu, H.
    Yang, X.
    Zhang, C.
    Xu, L.
    Liu, Z.
    Cai, J.
    Ma, J.
    Dai, S.
    Tao, G.
    Cheng, H.
    Sun, X.
    DISEASES OF THE ESOPHAGUS, 2016, 29 (03) : 215 - 223
12345